Xeris Biopharma Holdings (NASDAQ:XERS), Inc. (Nasdaq: XERS) has presented a post-hoc analysis from its SONICS study on the effects of its treatment levoketoconazole (Recorlev) in adults with Cushing’s syndrome at ENDO 2024 in Boston.
The study demonstrated that patients with lower baseline mean urine-free cortisol (mUFC) levels normalized at higher rates than those with more severe disease.
These patients also required lower doses of Recorlev and experienced fewer liver-related adverse events.
James Meyer, Xeris’ Senior Director of Publications and Medical Communications, stated: "The results of this analysis suggest that patients with Cushing’s syndrome/disease with lower mUFC(s) normalize at a higher rate than those with more severe disease and may require lower doses of Recorlev and experience lower rates of liver-related adverse events.
"This exploratory analysis brings further perspective to the importance of individualizing and tailoring medical management."
The analysis included 92 patients treated with levoketoconazole, stratified into three groups based on baseline mUFC levels.
Group 2 showed the highest response rate at 36.4%, compared to 31.6% for Group 1 and 23.8% for Group 3.
Group 3 required higher doses and had more liver-related adverse events.
Endogenous Cushing’s syndrome is a rare, serious, and potentially fatal endocrine disease caused by chronic elevated cortisol exposure–often the result of a benign tumor of the pituitary gland.